Chiesi

News

Chiesi fills permanent CEO role with Flagship's Khougazian

Chiesi has named Flagship's David Khougazian as its new permanent chief executive, following the departure of Giuseppe Accogli earlier this year.

News

UK postcode lottery ends for 'life-changing' cystinosis drug

Patients in England with rare disease cystinosis will soon be able to access a drug that has been available in other UK nations for up to three years

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Patients

Protecting continuity of care through sustainable respirator...

More attention is being paid to how care can be delivered in ways that maintain continuity for patients while also being environmentally responsible.

News

England poised to roll out drug for rare eye disease LHON

Patients in England with rare eye disorder LHON will finally get access to a Chiesi drug that has been available in the rest of the UK for years.

Digital

Digital health technologies and rare diseases: Enhancing the...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an honorarium for his participation and contribution to this webinar.

Chiesi fills permanent CEO role with Flagship's Khougazian

UK postcode lottery ends for 'life-changing' cystinosis drug

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Protecting continuity of care through sustainable respirator...

England poised to roll out drug for rare eye disease LHON

Digital health technologies and rare diseases: Enhancing the...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Chiesi

Editor's Picks